GIST Clinical Trial
Official title:
A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
Status | Recruiting |
Enrollment | 94 |
Est. completion date | June 2027 |
Est. primary completion date | March 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female =18 years of age - Module A: Part 1 and Part 2: Module A Part 1 and Part 2 DCC-3116 combination closed on January 8, 2024, with no participants enrolled. - Module B: Only for Part 1 (Safety/Dose-finding): - Pathologically confirmed diagnosis of GIST with a KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation - Must have progressed on at least one approved systemic regimen given in the locally advanced or metastatic setting or have documented intolerance to it - Must not have received prior ripretinib treatment - Module B: Only for Part 2 (Expansion) - Pathologically confirmed GIST with documented mutation in KIT exon 11 - Must have progressed on imatinib given in the locally advanced or metastatic setting or have been intolerant to imatinib and may not have received additional systemic therapy for GIST - Measurable disease - Must have a life expectancy of more than 3 months and an ECOG performance status of 0-1 - Adequate organ function and bone marrow reserve based on laboratory assessments performed at Screening - Must provide a fresh tumor biopsy and an archival tumor tissue sample, if available - Must agree to provide an on treatment biopsy Exclusion Criteria: - Must not have received the following within the specified time periods prior to the first dose of study drug: 1. Medications, including anticancer therapies, that are known strong or moderate inhibitors or inducers of CYP3A4 or P-glycoprotein (P-gp) including certain herbal medications (eg, St. John's wort): 14 days or 5×the half-life of the medication (whichever is longer) 2. Other anticancer therapies and any investigational therapies with a known safety and PK profile: 14 days or 5×the half-life of the medication (whichever is shorter) 3. Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days 4. Grapefruit or grapefruit juice: 14 days - Have not recovered from all clinically relevant toxicities from prior therapy - New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug - Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal disease - Malabsorption syndrome - Bone disease that requires ongoing treatment or has required treatment within 6 months of signing the informed consent form - Radiation for indications other than bone disease must have been completed 4 weeks prior to first dose of study drug, unless it consisted of limited field palliative radiation, including whole brain radiation, which must have been completed at least 2 weeks prior to first dose of study drug - Major surgery within 4 weeks of the first dose of study drug - Active HIV, Hepatitis B or Hepatitis C infection |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio |
United States | START Midwest | Grand Rapids | Michigan |
United States | UCLA Department of Medicine-Hematology/Oncology | Los Angeles | California |
United States | Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York |
United States | Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Oregon Health & Science University | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Deciphera Pharmaceuticals LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse Events (Escalation Phase) | Identify the observed adverse events and serious adverse events associated with DCC-3116 in combination with other anticancer therapies. | Approximately 24 months | |
Primary | Recommended Phase 2 Doses (RP2D) (Escalation Phase) | Identify the dose-limiting toxicities for each dose level tested and determine the recommended Phase 2 doses of DCC-3116 in combination with other anticancer therapies. | Approximately 18 months | |
Primary | Objective response rate (ORR) (Expansion Phase) | Proportion of participants who achieve CR or PR per histology-specific consensus response criteria. | Approximately 24 months | |
Secondary | Duration of response (DoR) | DoR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) per histology-specific consensus response criteria until the first date that the progressive disease is objectively documented or death, whichever occurs first. | Approximately 24 months | |
Secondary | Disease Control Rate (DCR) | The DCR is defined as the proportion of participants who achieve CR, PR, or stable disease (SD) per histology-specific consensus response criteria. | Approximately 24 months | |
Secondary | Time to response | Time to response is defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per histology-specific consensus response criteria. | Approximately 24 months | |
Secondary | Progression-free survival (PFS) | PFS is defined as the time from initiation of treatment until documented disease progression per histology-specific consensus response criteria or death, whichever occurs first. | Approximately 24 months | |
Secondary | Overall Survival (OS) | OS is defined as the time from initiation of treatment until death. | Approximately 48 months | |
Secondary | Maximum observed concentration (Cmax) | Measure the maximum observed concentration of DCC-3116 combinations. | Predose and up to 12 hours postdose | |
Secondary | Time to maximum observed concentration (Tmax) | Measure the time to maximum plasma concentration of DCC-3116 combinations. | Predose and up to 12 hours postdose | |
Secondary | Minimum observed concentration (Cmin) | Measure the minimum observed concentration of DCC-3116 combinations. | Predose and up to 12 hours postdose | |
Secondary | Area under the concentration-time curve (AUC) | Measure the AUC of DCC-3116 combinations. | Predose and up to 12 hours postdose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
Active, not recruiting |
NCT03556384 -
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Recruiting |
NCT05895942 -
Exploring the Molecular Mechanism Based on KIT Mutation
|
||
Completed |
NCT01459757 -
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
|
N/A | |
Completed |
NCT00979381 -
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
|
N/A | |
Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
Completed |
NCT04599660 -
Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
|
||
Completed |
NCT05400018 -
Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
|
||
Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04825470 -
Liver Transplantation for Unresectable GIST Liver Metastases
|
N/A | |
Recruiting |
NCT00687778 -
11C-Acetate PET/CT Non-FDG-Avid Tumors
|
N/A | |
Completed |
NCT00979329 -
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
|
N/A | |
Active, not recruiting |
NCT04927260 -
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
|
||
Completed |
NCT03465722 -
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
|
Phase 3 | |
Completed |
NCT03880617 -
Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Completed |
NCT01323400 -
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
|
Phase 2 | |
Recruiting |
NCT05804331 -
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
|
||
Completed |
NCT01874665 -
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
|
Phase 2 |